Title: Canakinumab for Atherosclerotic Disease
Design: Randomized, double-blind, placebo-controlled, event-driven phase 3 trial
Objective: To assess if canakinumab (Ab against interleukin-1β) reduce the recurrence CV events in patients with a history of MI and hs-CRP ≥ 2mg/L.
Year of publication: 2017
Inclusion Criteria: patients (age ≥ 18) with history of MI in prior 30 days and hsCRP of ≥2 mg/L. > (results only for 150 mg)
Comparison groups: Canakinumab, 150 mg (n=2,284) vs placebo (n=3,344)
Conclusion: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo.
Source: Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. NEJM 2017. 377(12):1119-1131.